These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15140331)

  • 1. Cost effectiveness of oral triptan therapy: a trans-national comparison based on a meta-analysis of randomised controlled trials.
    Belsey JD
    Curr Med Res Opin; 2004 May; 20(5):659-69. PubMed ID: 15140331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic analysis of triptan therapy for acute migraine: a Medicaid perspective.
    Mullins CD; Subedi PR; Healey PJ; Sanchez RJ
    Pharmacotherapy; 2007 Aug; 27(8):1092-101. PubMed ID: 17655509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project).
    Cutrer FM; Goadsby PJ; Ferrari MD; Lipton RB; Dodick DW; McCrory D; Williams P
    Clin Ther; 2004 Sep; 26(9):1533-45. PubMed ID: 15531016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Migraine treatment with rizatriptan and non-triptan usual care medications: a pharmacy-based study.
    Cady R; Martin V; Adelman J; Diamond M; Sajjan S; Hu XH
    Headache; 2004 Oct; 44(9):900-7. PubMed ID: 15447699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Utilizing the strength(s) of rizatriptan 10 mg: cost effective against migraine attacks].
    MMW Fortschr Med; 2009 Mar; 151(13):92-3. PubMed ID: 19504831
    [No Abstract]   [Full Text] [Related]  

  • 6. A pharmacoeconomic evaluation of oral triptans in the treatment of migraine in Italy.
    Gori S; Morelli N; Acuto G; Caiola F; Iudice A; Murri L
    Minerva Med; 2006 Dec; 97(6):467-77. PubMed ID: 17213783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians.
    Lipton RB; Cutrer FM; Goadsby PJ; Ferrari MD; Dodick DW; McCrory D; Liberman JN; Williams P
    Curr Med Res Opin; 2005 Mar; 21(3):413-24. PubMed ID: 15811210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Economic evaluation of acute migraine attack treatment with triptans in Spain].
    Gracia-Naya M; Rejas Gutiérrez J; Latorre Jiménez A; González Garcia P
    Neurologia; 2005 Apr; 20(3):121-32. PubMed ID: 15815947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine.
    Chen LC; Ashcroft DM
    Headache; 2008 Feb; 48(2):236-47. PubMed ID: 18179569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of oral triptan therapy in Sweden.
    Ramsberg J; Henriksson M
    Cephalalgia; 2007 Jan; 27(1):54-62. PubMed ID: 17212684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic comparison of oral triptans for management of acute migraine: implications for managed care.
    Reeder CE; Steadman S; Goldfarb SD
    Am J Manag Care; 2002 Feb; 8(3 Suppl):S80-4. PubMed ID: 11859908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rizatriptan. Convenience and consistency.
    Evans RW
    Postgrad Med; 2000 Sep; 108(3 Suppl):10-5. PubMed ID: 19667525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using patient-centered endpoints to determine the cost-effectiveness of triptans for acute migraine therapy.
    Kelman L; Von Seggern RL
    Am J Ther; 2006; 13(5):411-7. PubMed ID: 16988536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain--results of a model-based meta-analysis that accounts for encapsulation.
    Mandema JW; Cox E; Alderman J
    Cephalalgia; 2005 Sep; 25(9):715-25. PubMed ID: 16109054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Probabilistic cost-effectiveness analysis of oral eletriptan in the treatment of acute migraine in Portugal].
    Félix JM; Inês MS; Acosta CM
    Acta Med Port; 2005; 18(1):77-87. PubMed ID: 16202337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infrequent or non-response to oral sumatriptan does not predict response to other triptans--review of four trials.
    Dahlöf CG
    Cephalalgia; 2006 Feb; 26(2):98-106. PubMed ID: 16426262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute treatment of paediatric migraine: a meta-analysis of efficacy.
    Silver S; Gano D; Gerretsen P
    J Paediatr Child Health; 2008 Jan; 44(1-2):3-9. PubMed ID: 17854415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population.
    Sheftell FD; Feleppa M; Tepper SJ; Volcy M; Rapoport AM; Bigal ME
    Headache; 2004; 44(7):661-8. PubMed ID: 15209687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost effectiveness of treatment with triptanes in Spain].
    Gracia Naya M
    Rev Neurol; 2001 Nov 16-30; 33(10):921-4. PubMed ID: 11785001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of evidence-based medicine and meta-analytic reviews in migraine.
    Tfelt-Hansen P
    Cephalalgia; 2006 Nov; 26(11):1265-74. PubMed ID: 17059433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.